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Abstract
There has been discussion and debate in the medical literature regarding the clinical
value of PET/CT scans in ovarian cancer, particularly focusing on evidence whether the
technology is of predictive versus solely prognostic utility. In the somewhat unusual case
reported here, the results of the PET/CT scan were extremely helpful in developing a
rational management strategy. The case emphasizes the critical need to specifically
address the issue of whether data generated from an expensive diagnostic test will be
useful in an individual patient’s management before it is obtained.

Introduction

There has been considerable discussion in the gynecologic cancer literature regarding
the potential benefits associated with the performance of a PET/CT scan in women with
epithelial ovarian cancer, particularly in the setting of suspected or documented recurrent
disease [1–7]. One recent report noted that 60% of patients with recurrent ovarian cancer
had their treatment plan modified based on the results of this imaging procedure [1].
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However, it remains unknown how such changes in management influence the
patient’s outcome (overall, symptom-free or progression-free survival, quality of life) [8,
9]. Specifically, one must inquire if the data obtained through the conduct of this
expensive diagnostic test is of predictive utility (helps select a specific management plan
predicted to be beneficial due the study findings) or only of prognostic value (defines a
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situation where the patient is more/less likely to have a relatively poor/good outcome,
independent of any particular management strategy) [8, 9].
The clinical course of a woman with a long history of epithelial ovarian cancer
provides a relevant example of the potential for PET/CT scanning to modify management
in an individual patient and where it is rational to argue that the specific diagnostic data
in rather unique settings can be considered crucial in defining optimal care.

Case Report
A 70-year-old woman presented in January of 2002 with a complex pelvic mass and a CA-125 in the
350 U/ml range. Her history was complicated by a history of breast cancer. She is of Ashkenazi heritage
and therefore underwent genetic counseling and BRCA testing. These were negative.
The patient underwent an exploratory laparotomy and staging with complete resection of all gross
disease. Final pathology revealed a moderately differentiated papillary serous carcinoma of the ovary.
She was treated with 6 cycles of carboplatin and paclitaxel, achieving a complete response as measured
by her CA-125 antigen level. Her post-treatment course was complicated by moderate neuropathy that
improved but did not completely resolve.
Two years after the treatment the patient experienced a chronic bowel obstruction secondary to
adhesions that caused such distressing symptoms that she underwent laparoscopic adhesiolysis. The
procedure resulted in resolution of her symptoms. There was no evidence of disease with biopsies and
washings being negative.
Immediately postoperatively she had a low normal CA-125 level (<13 U/ml range). Over the next 2
years the CA-125 rose from this level to 18 U/ml, and then ultimately to 28 U/ml. The marker remained
stable over the next 2 years ranging from 28 to 40 U/ml. CT scans were negative. In 2008, the CA-125
began to rise slowly and CT scans demonstrated only a small amount of lymphadenopathy with a 2-cm
node in the left common ileac area not easily accessible for CT-guided biopsy. Attempted biopsy was
negative. Her CA-125 began to rise more rapidly and in December of 2008 increased to 80 U/ml. The
CT scan of the abdomen/pelvis remained unremarkable.
In March of 2009, the marker increased to 118 U/ml. CT remained negative and a PET/CT scan was
obtained. This test demonstrated military disease throughout the pelvis with many nodules <1 cm, with
no disease >1 cm in diameter. She did have one retroperitoneal node that was approximately 1.5 cm.
After an extensive discussion with the patient regarding neuropathy and other comorbidities, she
and her physician elected to initiate retreatment with carboplatin and gemcitabine. After 3 cycles her
CA-125 level normalized. The plan is to continue to complete 6 cycles of this regimen, with a follow-up
PET/CT scan. If the PET/CT is negative or mildly positive for residual disease, antiestrogen therapy will
be considered.

Discussion

Considering the substantial costs associated with novel diagnostic tests, and in
particular imaging technology, it is appropriate to question the importance of ‘another
result’ that indicates that the patient will have a relatively favorable versus a relatively
unfavorable outcome (prognostic utility), but where the data itself does not clearly define
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Considerable uncertainty surrounds the question of the utility of many innovative
diagnostic techniques in the oncology arena. In addition to the issue of the specificity
(does a ‘positive test’ result indicate the presence of cancer, and only cancer) and
sensitivity (does a ‘negative test’ result indicate the absence of cancer), it is increasingly
essential to inquire if the information provided is of predictive value or solely of
prognostic significance [9].
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a known beneficial management strategy that would only have been employed because of
the specific test result (predictive utility).
For example, in recurrent ovarian cancer, a PET/CT finding of ‘diffuse disease
throughout the peritoneal cavity’, versus the observation of ‘relatively localized cancer’,
while potentially of prognostic value, will not necessarily permit the selection of therapy
that impacts survival [8]. Further, the argument that the finding of apparently localized
disease should lead to surgery, while the observation of diffuse disease should not, is
currently not supported by any evidence-based (randomized phase 3) clinical trials. Thus,
we do not know if surgery (to remove the observed masses) in this setting is superior to
initial treatment with cytotoxic chemotherapy, and conversely it is unknown if patients
with ‘diffuse disease’ (as documented on PET/CT) are unable to benefit from surgery
designed to completely remove all macroscopic cancer (of course, leaving the ‘diffuse
microscopic residual’).
In the case presented here, there was reasonable uncertainty regarding optimal disease
management based on the prior medical history (known breast and ovarian cancer, long
treatment-free interval, persisting neuropathy), as well as nonspecific physical signs and
symptoms and routine diagnostic tests (abdominal/pelvic CT scan, CA-125). In was
appropriate to argue in this specific individual with a long treatment-free interval and a
mass (enlarged lymph node) that could potentially be easily removed that surgical
resection might permit the patient to go for an additional extended period of time
without the reintroduction of chemotherapy. Conversely, it was equally possible that the
lymph node was not the source of the increasing CA-125 levels, and may even have been
nonmalignant.
The PET/CT scan findings revealed a very diffuse process in the absence of any large
masses that would be amenable to surgical resection. The test results provided relevant
information that reinforced the physician’s decision to employ systemic treatment in this
individual. Of note, in this patient, with a set of particularly unique clinical features, the
PET/CT could be utilized in the selection of a specific clinical plan that also included
consideration of those unique characteristics.
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In the absence of evidence-based data demonstrating the utility of this procedure in the
management of patients with ovarian cancer, it is essential that clinicians prospectively
consider (prior to obtaining the test): (a) how the information generated from the
performance of this expensive imaging modality will influence the selection of specific
treatment; (b) whether such information will be of genuine utility in a particular patient;
(c) and whether there are alternative, more cost-effective approaches (physical exam;
CT-scan; CA-125 value alone; knowledge of the natural history of the malignancy) that
may be employed to define appropriate care.
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